197 related articles for article (PubMed ID: 35465239)
1. Evaluation of
Alfouzan W; Dhar R; Mohsin J; Khamis F; Mokaddas E; Abdullah A; Mustafa AS; Otero A; Wanis P; Matar SH; Khalil S; Alekseeva I; Young K
JAC Antimicrob Resist; 2022 Apr; 4(2):dlac035. PubMed ID: 35465239
[TBL] [Abstract][Full Text] [Related]
2. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
3. Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.
Tuon FF; Cieslinski J; Rodrigues SDS; Serra FB; Paula MD
Braz J Infect Dis; 2020; 24(2):96-103. PubMed ID: 32360070
[TBL] [Abstract][Full Text] [Related]
4. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.
Karlowsky JA; Lob SH; Siddiqui F; Polis T; Vallejo JL; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Jun; 6(3):dlae077. PubMed ID: 38799180
[TBL] [Abstract][Full Text] [Related]
6. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
BMC Microbiol; 2021 Mar; 21(1):74. PubMed ID: 33676406
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Cantón R; Loza E; Arcay RM; Cercenado E; Castillo FJ; Cisterna R; Gálvez-Benítez L; González Romo F; Hernández-Cabezas A; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
Rev Esp Quimioter; 2021 Jun; 34(3):228-237. PubMed ID: 33645948
[TBL] [Abstract][Full Text] [Related]
8. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and
Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2023 Aug; 5(4):dlad098. PubMed ID: 37577157
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/Tazobactam Activity Against Drug-Resistant
Pfaller M; Shortridge D; Chen WT; Sader H; Castanheira M
Infect Drug Resist; 2022; 15():6739-6753. PubMed ID: 36444213
[TBL] [Abstract][Full Text] [Related]
10. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
11. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Shortridge D; Streit J; Pfaller M; Tulloch M; Chen WT; Castanheira M
J Glob Antimicrob Resist; 2022 Dec; 31():98-103. PubMed ID: 35988706
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Karlowsky JA; Lob SH; Khan TK; Chen WT; Woo PCY; Seto WH; Ip M; Leung SWM; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2023 Jun; 33():260-266. PubMed ID: 37086892
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
Sader HS; Carvalhaes CG; Duncan LR; Flamm RK; Shortridge D
J Antimicrob Chemother; 2020 Oct; 75(10):2907-2913. PubMed ID: 32653914
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
16. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).
Beirão EM; Rodrigues SDS; Andrade TK; Serra FB; Paula MDN; Polis TJB; Gales AC
Braz J Infect Dis; 2020; 24(4):310-321. PubMed ID: 32663440
[TBL] [Abstract][Full Text] [Related]
17. Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
Shortridge D; Duncan LR; Pfaller MA; Flamm RK
Int J Antimicrob Agents; 2019 May; 53(5):637-643. PubMed ID: 30716448
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against
Shortridge D; Pfaller MA; Arends SJR; Raddatz J; DePestel DD; Flamm RK
Open Forum Infect Dis; 2019 Jun; 6(6):ofz240. PubMed ID: 31263733
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
20. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
